Stock listing
Shanghai:603387 Getein Biotech, Inc. (基蛋生物) 股价
Follow Getein Biotech, Inc. into a list and get an email when it puts out news.
Share price · SSE:603387
¥7.99 CNY -0.28 (-3.4%)
Close on Nov 20, 2026
- Day range
- ¥7.87 – ¥8.09 CNYNov 20, 2026
- Volume
- 7.68M sharesNov 20, 2026
- Market cap
- ¥4.05B CNYAt the close on Nov 20, 2026 · price × 507.2M shares outstanding
- 52-week range
- ¥7.37 – ¥11.42 CNYLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- ¥82.05M CNYMedian day 8.15M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · SSE:603387 · CNY, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| ¥7.99 | -0.28 | -3.4% | ¥8.02 | ¥8.09 | ¥7.87 | 7,680,589 | |
| ¥8.27 | +0.01 | +0.1% | ¥8.29 | ¥8.31 | ¥8.13 | 5,065,720 | |
| ¥8.26 | +0.06 | +0.7% | ¥8.17 | ¥8.30 | ¥8.10 | 5,579,900 | |
| ¥8.20 | -0.04 | -0.5% | ¥8.20 | ¥8.30 | ¥8.13 | 4,819,000 | |
| ¥8.24 | -0.31 | -3.6% | ¥8.51 | ¥8.55 | ¥8.21 | 11,332,396 | |
| ¥8.55 | +0.04 | +0.5% | ¥8.52 | ¥8.60 | ¥8.46 | 7,470,734 | |
| ¥8.51 | +0.01 | +0.1% | ¥8.49 | ¥8.51 | ¥8.44 | 5,553,996 | |
| ¥8.50 | +0.05 | +0.6% | ¥8.50 | ¥8.56 | ¥8.47 | 5,899,256 | |
| ¥8.45 | -0.06 | -0.7% | ¥8.56 | ¥8.65 | ¥8.43 | 5,999,320 | |
| ¥8.51 | -0.21 | -2.4% | ¥8.57 | ¥8.68 | ¥8.50 | 7,560,092 | |
| ¥8.72 | +0.12 | +1.4% | ¥8.56 | ¥8.74 | ¥8.55 | 9,682,080 | |
| ¥8.60 | +0.14 | +1.7% | ¥8.45 | ¥8.63 | ¥8.40 | 9,170,016 | |
| ¥8.46 | -0.01 | -0.1% | ¥8.46 | ¥8.57 | ¥8.34 | 8,150,236 | |
| ¥8.47 | +0.02 | +0.2% | ¥8.48 | ¥8.60 | ¥8.32 | 11,411,084 | |
| ¥8.45 | -0.09 | -1.1% | ¥8.51 | ¥8.83 | ¥8.33 | 9,384,452 | |
| ¥8.54 | -0.17 | -2.0% | ¥8.63 | ¥8.75 | ¥8.51 | 7,258,153 | |
| ¥8.71 | +0.06 | +0.7% | ¥8.54 | ¥8.77 | ¥8.37 | 10,989,965 | |
| ¥8.65 | -0.47 | -5.2% | ¥9.15 | ¥9.22 | ¥8.62 | 9,373,585 | |
| ¥9.12 | +0.21 | +2.4% | ¥8.90 | ¥9.25 | ¥8.83 | 8,490,677 | |
| ¥8.91 | +0.06 | +0.7% | ¥8.82 | ¥8.95 | ¥8.53 | 8,138,200 | |
| ¥8.85 | -0.29 | -3.2% | ¥9.21 | ¥9.21 | ¥8.83 | 7,514,976 | |
| ¥9.14 | -0.01 | -0.1% | ¥9.21 | ¥9.44 | ¥9.11 | 7,120,057 | |
| ¥9.15 | +0.17 | +1.9% | ¥9.01 | ¥9.21 | ¥8.94 | 6,661,439 | |
| ¥8.98 | -0.19 | -2.1% | ¥9.11 | ¥9.28 | ¥8.82 | 8,798,100 | |
| ¥9.17 | -0.16 | -1.7% | ¥9.38 | ¥9.69 | ¥9.06 | 8,529,389 | |
| ¥9.33 | -0.16 | -1.7% | ¥9.25 | ¥9.48 | ¥9.19 | 7,296,983 | |
| ¥9.49 | -0.15 | -1.6% | ¥9.76 | ¥9.76 | ¥9.38 | 5,855,183 | |
| ¥9.64 | -0.12 | -1.2% | ¥9.71 | ¥9.71 | ¥9.40 | 8,884,492 | |
| ¥9.76 | -0.29 | -2.9% | ¥10.03 | ¥10.05 | ¥9.76 | 8,576,008 | |
| ¥10.05 | -0.11 | -1.1% | ¥10.05 | ¥10.10 | ¥9.68 | 13,507,548 | |
| ¥10.16 | +0.15 | +1.5% | ¥10.10 | ¥10.23 | ¥9.91 | 13,157,760 | |
| ¥10.01 | +0.20 | +2.0% | ¥9.81 | ¥10.10 | ¥9.75 | 10,190,729 | |
| ¥9.81 | -0.10 | -1.0% | ¥9.91 | ¥9.97 | ¥9.74 | 7,433,074 | |
| ¥9.91 | +0.09 | +0.9% | ¥9.87 | ¥10.11 | ¥9.84 | 9,617,354 | |
| ¥9.82 | -0.13 | -1.3% | ¥9.85 | ¥10.05 | ¥9.81 | 8,887,300 | |
| ¥9.95 | -0.14 | -1.4% | ¥10.00 | ¥10.12 | ¥9.90 | 11,017,375 | |
| ¥10.09 | +0.15 | +1.5% | ¥9.94 | ¥10.25 | ¥9.80 | 19,290,213 | |
| ¥9.94 | +0.52 | +5.5% | ¥9.48 | ¥9.98 | ¥9.43 | 18,305,978 | |
| ¥9.42 | -0.06 | -0.6% | ¥9.35 | ¥9.59 | ¥9.30 | 9,810,621 | |
| ¥9.48 | +0.27 | +2.9% | ¥9.27 | ¥9.49 | ¥9.21 | 10,606,796 | |
| ¥9.21 | +0.13 | +1.4% | ¥9.05 | ¥9.23 | ¥9.03 | 4,372,942 | |
| ¥9.08 | -0.14 | -1.5% | ¥9.16 | ¥9.22 | ¥9.03 | 4,976,560 | |
| ¥9.22 | +0.13 | +1.4% | ¥9.01 | ¥9.28 | ¥9.01 | 4,497,649 | |
| ¥9.09 | -0.14 | -1.5% | ¥9.18 | ¥9.24 | ¥8.99 | 5,942,236 | |
| ¥9.23 | -0.24 | -2.5% | ¥9.48 | ¥9.48 | ¥9.19 | 5,157,089 | |
| ¥9.47 | +0.02 | +0.2% | ¥9.39 | ¥9.54 | ¥9.28 | 6,817,135 | |
| ¥9.45 | +0.23 | +2.5% | ¥9.25 | ¥9.48 | ¥9.17 | 7,980,550 | |
| ¥9.22 | -0.05 | -0.5% | ¥9.22 | ¥9.39 | ¥9.17 | 5,222,620 | |
| ¥9.27 | -0.03 | -0.3% | ¥9.29 | ¥9.42 | ¥9.19 | 6,309,387 | |
| ¥9.30 | -0.09 | -1.0% | ¥9.42 | ¥9.46 | ¥9.27 | 6,005,519 | |
| ¥9.39 | -0.13 | -1.4% | ¥9.48 | ¥9.51 | ¥9.33 | 5,996,736 | |
| ¥9.52 | +0.20 | +2.1% | ¥9.30 | ¥9.57 | ¥9.26 | 10,900,912 | |
| ¥9.32 | -0.01 | -0.1% | ¥9.27 | ¥9.35 | ¥9.20 | 7,592,959 | |
| ¥9.33 | -0.08 | -0.9% | ¥9.53 | ¥9.54 | ¥9.30 | 9,214,544 | |
| ¥9.41 | -0.12 | -1.3% | ¥9.55 | ¥9.79 | ¥9.33 | 14,309,597 | |
| ¥9.53 | +0.19 | +2.0% | ¥9.33 | ¥9.92 | ¥9.33 | 15,064,899 | |
| ¥9.34 | +0.16 | +1.7% | ¥9.13 | ¥9.35 | ¥9.09 | 8,155,160 | |
| ¥9.18 | -0.24 | -2.5% | ¥9.38 | ¥9.38 | ¥9.08 | 11,107,073 | |
| ¥9.42 | -0.23 | -2.4% | ¥9.51 | ¥9.56 | ¥9.23 | 13,284,135 | |
| ¥9.65 | +0.40 | +4.3% | ¥9.27 | ¥9.72 | ¥9.27 | 19,612,188 |
Splits
4 splits since 2018 · SSE:603387 · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 7-for-5 | Split | |
| 7-for-5 | Split | |
| 7-for-5 | Split | |
| 7-for-5 | Split |
- Ticker
- Shanghai:603387
- Asset type
- Stock
- Sector
- Health care
- Industry
- Diagnostics & research services
- Exchange
- Shanghai
- Currency
- CNY
What changed lately
Latest news release · Nov 4, 2026
(603387)"Getein Biotech, Inc."Announcement on Progress in Repurchasing Shares through Call Auction
Latest news
(603387)"Getein Biotech, Inc."Announcement on Progress in Repurchasing Shares through Call Auction
Nov 4, 2026
Closed ¥8.60 (+1.7%) on Nov 4, 2026
(603387)"Getein Biotech, Inc"Announcement on Outline of the Q3 2026 Online Performance Briefing
Nov 4, 2026
Closed ¥8.60 (+1.7%) on Nov 4, 2026
(603387)"Getein Biotech, Inc"Report for Q3 2026
Oct 28, 2026
Closed ¥8.71 (+0.7%) on Oct 28, 2026
(603387)"Getein Biotech, Inc"Announcement on Convening the Q3 2026 Online Performance Briefing
Oct 28, 2026
Closed ¥8.71 (+0.7%) on Oct 28, 2026
Announcement on Outline of the 2026 Semi-annual Online Performance Briefing
Sep 16, 2026
Closed ¥9.21 (+1.4%) on Sep 16, 2026
Announcement on Adjustment of Upper Limit of Repurchase Price Following Implementation of Dividend Distribution for the First Half of 2026
Sep 12, 2026
Closed ¥9.22 (+1.4%) on Sep 14, 2026
Announcement on Obtaining a Commitment Letter for a Special Loan for Share Repurchase from a Financial Institution
Sep 1, 2026
Closed ¥9.52 (+2.1%) on Sep 1, 2026
Announcement on Resolutions of the 14th Meeting of the 4th Board of Directors
Aug 27, 2026
Closed ¥9.41 (-1.3%) on Aug 27, 2026
Announcement on Progress in Repurchasing Shares through Call Auction
Aug 4, 2026
Closed ¥9.04 (+1.6%) on Aug 4, 2026
Announcement on the Progress of Implementing the "Settlement Agreement" and Transferring Equity Interests in a Controlled Subsidiary
Jul 17, 2026
Closed ¥8.79 (-5.0%) on Jul 17, 2026
Getein Biotech, Inc. on 6ix
- Sector
- Health care
- Industry
- Diagnostics & research services
- News releases
- 24 in the last 12 months · 51 in all · newest Nov 4, 2026 · oldest 2024
Valuation
P/E 13.8× against a median of 69.9×: the lowest of 5 Diagnostics & research services companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- ¥2.39B CNY
- P/E
- 13.8×
- EV/sales
- 2.1×
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 1.4×
- Gross margin
- 69.9%
- Operating margin
- 27.6%
- Net margin
- 26.3%
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Getein Biotech, Inc. Class A · SSE:603387 | US$608.2M | US$358.4M | 13.8× | 2.1× | n/a | 1.4× | 26.3% | 0.0× | n/a |
| Maccura Biotechnology Co., Ltd. Class A · SZSE:300463 | US$722.4M | US$677.6M | n/a | 2.1× | n/a | 0.8× | −1.5% | 0.1× | n/a |
| R&G PharmaStudies Co., Ltd. Class A · SZSE:301333 | US$706.0M | US$456.1M | 40.4× | 3.2× | n/a | 2.4× | 12.2% | 0.0× | n/a |
| OmniAb, Inc. · NASDAQ:OABI | US$679.7M | US$615.5M | n/a | 15.3× | n/a | 2.7× | −108.1% | 0.0× | 1.29 |
| SD Biosensor, Inc. · KRX:137310 | US$655.8M | US$520.0M | n/a | 0.9× | 11.5× | 0.4× | −98.8% | 0.1× | n/a |
| PharmaResources (Shanghai) Co., Ltd Class A · SZSE:301230 | US$641.2M | US$600.8M | 149× | 5.5× | n/a | 4.2× | 4.0% | 0.0× | n/a |
| QuidelOrtho Corporation · NASDAQ:QDEL | US$570.9M | US$828.9M | n/a | 0.3× | 2.5× | 0.3× | −14.2% | 0.2× | 2.56 |
| Shanghai Obio Technology (Group) Corp., Ltd. Class A · SSE:688238 | US$542.6M | US$548.0M | n/a | 12.4× | n/a | 2.9× | −74.6% | 0.5× | n/a |
| Frontage Holdings Corp. · HKEX:1521 | US$539.7M | US$643.1M | 79.5× | 2.5× | 12.6× | 1.5× | 2.6% | 0.4× | n/a |
| Boji Medical Technology Co., Ltd Class A · SZSE:300404 | US$524.0M | US$473.9M | 60.3× | 3.1× | n/a | 3.2× | 5.7% | 0.0× | n/a |
| Myriad Genetics, Inc. · NASDAQ:MYGN | US$523.7M | US$537.7M | n/a | 0.7× | n/a | 1.9× | −16.1% | 0.5× | 0.67 |
| Median of the others | US$606.0M | US$574.4M | 69.9× | 2.8× | 11.5× | 2.1× | −7.9% | 0.1× | 1.29 |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q1 2023 | Apr 27, 2023 | +10.6% |
| Q3 2022 | Oct 27, 2022 | −1.0% |
| Q2 2022 | Aug 24, 2022 | −6.6% |
| Q1 2022 | Apr 27, 2022 · Before open | +6.6% |
| Quarter to Sep 30, 2021 | Oct 29, 2021 | +2.0% |
| Quarter to Jun 30, 2021 | Aug 17, 2021 · Before open | −0.9% |
| Quarter to Mar 31, 2021 | Apr 27, 2021 · After close | −10.0% |
| Quarter to Dec 31, 2020 | Mar 3, 2021 · Before open | +8.1% |
Financials
Annual, in CNY
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.05B | 1.16B | 1.37B | 1.82B | 1.40B | 1.12B | 968.2M | 686.2M | 488.6M | 369.1M |
| Cost of revenue | 317.7M | 374.4M | 479.7M | 671.6M | 485.4M | 414.4M | 264.9M | 144.1M | 88.6M | 69.4M |
| Gross profit | 734.0M | 790.4M | 889.5M | 1.15B | 916.3M | 708.9M | 703.3M | 542.2M | 400.0M | 299.7M |
| Research and development | 157.4M | 181.2M | 218.0M | 223.2M | 163.4M | 119.1M | 104.7M | 80.6M | 54.0M | 39.3M |
| Selling, general and administrative | 79.6M | 95.7M | 106.8M | 103.9M | 90.6M | 75.9M | 63.2M | 54.9M | 37.7M | 68.6M |
| Operating income | 257.0M | 258.1M | 306.6M | 563.3M | 452.8M | 378.0M | 398.9M | 282.8M | 223.3M | 152.6M |
| Depreciation and amortization | 85.4M | 93.6M | 93.1M | 70.4M | 49.4M | 35.9M | 27.9M | 24.8M | 21.0M | 15.6M |
| EBITDA | 342.4M | 351.7M | 399.7M | 633.6M | 502.2M | 413.9M | 426.9M | 307.5M | 244.4M | 168.3M |
| Interest expense | 12.1M | 15.4M | 17.5M | 17.1M | 16.0M | 7.17M | 1.65M | 120.9K | 1.49M | 55.9K |
| Income before tax | 227.7M | 253.4M | 304.9M | 560.0M | 451.6M | 374.0M | 396.0M | 287.3M | 224.0M | 161.7M |
| Income tax | 23.6M | 20.9M | 56.0M | 39.6M | 43.7M | 46.0M | 36.6M | 30.2M | 23.3M | |
| Net income | 220.7M | 223.6M | 279.8M | 498.9M | 399.0M | 304.7M | 339.7M | 249.6M | 194.0M | 138.4M |
| Earnings per share, basic | 0.44 | 0.44 | 0.55 | 0.98 | 0.78 | 0.60 | 0.66 | 0.49 | 0.45 | 0.36 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 313.9M | 351.6M | 484.3M | 646.2M | 968.9M | 801.5M | 659.5M | 145.4M | 301.0M | 26.3M |
| Short-term investments | 912.6M | 648.9M | 451.9M | 511.1M | 612.7M | 594.9M | 467.4M | 634.1M | 167.1M | |
| Receivables | 359.5M | 407.8M | 478.6M | 496.9M | 446.0M | 472.0M | 247.8M | 79.3M | 33.4M | 31.9M |
| Inventory | 183.8M | 194.5M | 229.7M | 269.4M | 252.3M | 212.0M | 160.7M | 126.4M | 62.3M | 49.1M |
| Current assets | 2.30B | 1.86B | 2.15B | 2.40B | 2.37B | 2.12B | 1.57B | 1.28B | 1.05B | 279.2M |
| Property, plant and equipment | 556.5M | 452.2M | 369.6M | 296.8M | 231.4M | 174.9M | 122.5M | |||
| Goodwill | 12.0M | 309.7K | 26.1M | 26.1M | 26.1M | 26.1M | 309.7K | 309.7K | 309.7K | |
| Total assets | 3.76B | 3.71B | 3.77B | 3.68B | 3.14B | 2.70B | 2.01B | 1.57B | 1.27B | 434.1M |
| Accounts payable | 190.2M | 145.9M | 129.1M | 121.4M | 121.1M | 118.3M | 67.0M | 26.8M | 11.0M | 9.66M |
| Current liabilities | 855.2M | 940.0M | 977.9M | 958.1M | 813.5M | 656.6M | 316.9M | 180.0M | 111.7M | 85.3M |
| Long-term debt | 3.00M | 27.8M | 20.0M | |||||||
| Total debt | 577.2M | 644.0M | 591.0M | 496.5M | 384.8M | 95.0M | 31.2M | |||
| Total liabilities | 896.6M | 986.4M | 1.03B | 1.01B | 863.9M | 695.9M | 326.0M | 187.2M | 118.9M | 91.1M |
| Shareholders' equity | 2.75B | 2.62B | 2.56B | 2.48B | 2.11B | 1.84B | 1.62B | 1.35B | 1.14B | 340.1M |
| Shares outstanding | 507.2M | 508.3M | 508.7M | 509.1M | 511.5M | 507.9M | 512.1M | 509.6M | 432.7M | 379.7M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 392.6M | 423.0M | 333.2M | 483.0M | 432.4M | 185.5M | 225.7M | 187.1M | 191.9M | 155.9M |
| Capital spending | -150.6M | -156.4M | -258.1M | -217.4M | -179.6M | -113.5M | -124.8M | -110.7M | -61.4M | -39.3M |
| Free cash flow | 242.0M | 266.6M | 75.1M | 265.5M | 252.8M | 71.9M | 100.9M | 76.4M | 130.6M | 116.6M |
| Cash from investing | -348.1M | -356.8M | -760.4M | -254.6M | -238.7M | 261.8M | -345.5M | -519.3M | -82.3M | |
| Cash from financing | -213.7M | -145.9M | -45.9M | -28.9M | 200.0M | 25.9M | -1.51M | 602.8M | -59.2M | |
| Dividends paid | -103.2M | -111.0M | -219.4M | -123.2M | -93.2M | -104.2M | -76.3M | -59.8M | -68.2M | -59.3M |
| Share buybacks | -50.4M | -541.8K | -535.2K | -654.3K | ||||||
| Change in cash | -41.1M | -132.9M | -157.8M | -304.2M | 147.8M | 140.7M | 514.2M | -158.6M | 274.8M | 14.8M |
Filings
All 51 filings
Cap table
Built by 6ix from Getein Biotech, Inc. Class A’s releases
- Common shares
- 507,153,517
- Fully diluted
- 507,153,517
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 507,153,517 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 507,153,517 |
Log in to ask 6ix AI your own questions about Getein Biotech, Inc.